ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

Alexion gets rare-disease-focused Wilson

by Lisa M. Jarvis
April 15, 2018 | APPEARED IN VOLUME 96, ISSUE 16

Alexion Pharmaceuticals will pay roughly $855 million to acquire Wilson Therapeutics, a Swedish biotech firm focused on treatments for rare diseases. The move comes as Alexion tries to refill its pipeline and right its business in anticipation of a drop in sales of its rare-disease treatment Soliris. The centerpiece of the all-cash purchase is WTX101, a copper-binding agent in Phase III studies to treat Wilson disease, a rare genetic disorder marked by accumulation of copper in the liver, brain, and eyes.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment